πŸ‡ΊπŸ‡Έ FDA
Patent

US 10562850

Human plasma kallikrein inhibitors

granted A61PA61P17/00A61P17/10

Quick answer

US patent 10562850 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P17/00, A61P17/10, A61P7/00